文献速递肿瘤 PET/CT

68Ga-LNC1007与2-18F-FDG/68Ga-FAPI-02 PET/CT在多种癌症患者中的头对头比较

A Head-to-Head Comparison of 68Ga-LNC1007 and 2-18F-FDG/68Ga-FAPI-02 PET/CT in Patients With Various Cancers.
PubMed 文献 · Clin Nucl Med · 2023-09-02

本研究纳入61例10种不同癌症患者,50例配对行68Ga-LNC1007与2-18F-FDG PET/CT,11例配对行68Ga-LNC1007与68Ga-FAPI-02 PET/CT。68Ga-LNC1007 PET/CT检出全部55个原发肿瘤,而2-18F-FDG PET/CT视觉阳性45个(P=0.002)。68Ga-LNC1007是一种有前景的新型诊断性PET示踪剂,可能成为2-18F-FDG诊断肾细胞癌、肝细胞癌、骨转移和腹膜转移的更好替代。

要点

  • 68Ga-LNC1007 PET/CT检出全部55个原发肿瘤,2-18F-FDG PET/CT视觉阳性45个(P=0.002)。
  • 68Ga-LNC1007 PET/CT诊断肾细胞癌和肝细胞癌优于2-18F-FDG PET/CT。
  • 68Ga-LNC1007 PET/CT在骨转移和腹膜转移中显示更多PET阳性病灶及更高SUVmax。

核心结论

  • 68Ga-LNC1007是一种有前景的新型诊断性PET示踪剂,可用于多种恶性病变的显像。
  • 68Ga-LNC1007可能成为2-18F-FDG诊断肾细胞癌、肝细胞癌、骨转移和腹膜转移的更好替代。

研究设计与样本

  • 头对头比较研究,纳入61例10种不同癌症患者。
  • 50例患者配对行68Ga-LNC1007与2-18F-FDG PET/CT,11例患者配对行68Ga-LNC1007与68Ga-FAPI-02 PET/CT。
  • 最终诊断基于组织病理学结果和诊断性影像学。
  • 对24个原发肿瘤行FAP和整合素αvβ3免疫组化。

主要发现

  • 68Ga-LNC1007 PET/CT检出全部55个原发肿瘤,2-18F-FDG PET/CT视觉阳性45个原发肿瘤(P=0.002)。
  • 亚组分析显示68Ga-LNC1007 PET/CT诊断肾细胞癌和肝细胞癌优于2-18F-FDG PET/CT。
  • 与2-18F-FDG相比,68Ga-LNC1007 PET/CT在骨转移和腹膜转移中显示更多PET阳性病灶和更高SUVmax。
  • 原发肿瘤在68Ga-LNC1007 PET/CT上的SUVmax和肿瘤/本底比值远高于68Ga-FAPI-02 PET/CT,转移瘤亦观察到相同结果。
  • 免疫组化显示68Ga-LNC1007 PET定量的SUVmean与FAP表达水平相关(r=0.564,P=0.005)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: This head-to-head comparison study was designed to investigate the radiotracer uptake and clinical feasibility of using 68Ga-LNC1007, to detect the primary and metastatic lesions in patients with various types of cancer, and to compare the results with those of 2-18F-FDG PET/CT and 68Ga-FAPI-02 PET/CT. PATIENTS AND METHODS: Sixty-one patients with 10 different kinds of cancers were enrolled in this study. Among them, 50 patients underwent paired 68Ga-LNC1007 and 2-18F-FDG PET/CT, and the other 11 patients underwent paired 68Ga-LNC1007 and 68Ga-FAPI-02 PET/CT. The final diagnosis was based on histopathological results and diagnostic radiology. Immunohistochemistry for FAP and integrin αvβ3 was performed in 24 primary tumors. RESULTS: 68Ga-LNC1007 PET/CT detected all 55 primary tumors, whereas 2-18F-FDG PET/CT was visually positive for 45 primary tumors (P = 0.002). Furthermore, subgroup analysis showed that 68Ga-LNC1007 PET/CT was superior to 2-18F-FDG PET/CT in diagnosing renal cell carcinomas and hepatocellular carcinomas. For metastatic tumors, 68Ga-LNC1007 PET/CT revealed more PET-positive lesions and higher SUVmax for skeletal metastases and peritoneal metastases compared with 2-18F-FDG. The SUVmax and tumor-to-background ratio of primary tumors on 68Ga-LNC1007 PET/CT were much higher than those on 68Ga-FAPI-02 PET/CT, the same was also observed for metastatic tumors. Immunohistochemical results showed that the SUVmean quantified from 68Ga-LNC1007 PET was correlated with FAP expression level (r = 0.564, P = 0.005). CONCLUSIONS: 68Ga-LNC1007 is a promising new diagnostic PET tracer for imaging of various kinds of malignant lesions. It may be a better alternative to 2-18F-FDG for diagnosing renal cell carcinoma, hepatocellular carcinoma, skeletal metastases, and peritoneal metastases.

来源:Clin Nucl Med,查看原文。版权归原作者所有。

引用

  1. Zang J, Lin R, Wen X, et al. A Head-to-Head Comparison of 68Ga-LNC1007 and 2-18F-FDG/68Ga-FAPI-02 PET/CT in Patients With Various Cancers. Clin Nucl Med. 2023. PMID: 37682601. doi:10.1097/RLU.0000000000004820

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。